Related Experiment Video
Updated: Aug 25, 2025

Author Spotlight: Fabrication of a Low-Cost, Fiber-Coupled, and Air-Spaced Fabry-Pérot Etalon
Published on: February 3, 2023
A Detouring Experience Not Recommended: Lessons Learned from PF00299804.
Molly Li1,2, Kevin Mok3, Tony Mok1,2
1Department of Clinical Oncology, The Chinese University of Hong Kong, Hong Kong.
Second-generation EGFR TKI PF00299804 demonstrated potent inhibition and ability to overcome T790M resistance mutations in preclinical models. This review examines its development and lessons learned for non-small cell lung cancer (NSCLC) treatment.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Non-small cell lung cancer (NSCLC) patients with mutant EGFR benefit from tyrosine kinase inhibitors (TKIs).
- Acquired resistance, often due to the EGFR exon 20 T790M mutation, limits TKI efficacy.
- Second-generation EGFR TKIs aim to overcome resistance mechanisms.
More Related Videos
09:04Identifying Per- and Polyfluorinated Chemical Species with a Combined Targeted and Non-Targeted-Screening High-Resolution Mass Spectrometry Workflow
Published on: April 18, 2019
08:12Author Spotlight: Exploring Light-Driven Chemical Reactions and Energy-Harnessing Devices in Photochemical Research
Published on: February 16, 2024
Related Concept Videos
PD Controller: Design
Designing a continuous-data controller requires selecting and linking components like adders and integrators, which are fundamental in Proportional,...
Power Factor Correction